Middle aortic syndrome treated by stent implantation

G Brzezinska-Rajszys, S A Qureshi, J Ksiazyk, M Zubrzycka, A Kosciesza, K Kubicka, M Tynan

Abstract

Objectives—To determine outcome of stent implantation in patients with middle aortic syndrome.

Design—Prospective study, case series.

Setting—A tertiary paediatric cardiology centre in a children’s hospital.

Patients—Five patients, aged 4 to 17 years (mean 11.4 years), with upper limb hypertension due to middle aortic syndrome.

Intervention—Stents were implanted in the mid/lower thoracic/upper abdominal aorta.

Main outcome measure—Satisfactory deployment of stents and blood pressure control.

Results—In all patients, angiography showed long segment stenosis in the mid or lower thoracic/upper abdominal aorta. The pressure gradient was between 40 and 90 mm Hg (mean 63.2 mm Hg). Seven Palmaz stents were implanted. Immediately after implantation, the gradient decreased to between 0 and 35 mm Hg (mean 13.6 mm Hg). Angiography showed a satisfactory result with widely patent stents in all. In one patient, thrombosis of the stent occurred six days after implantation. This was successfully treated with infusion of alteplase, further balloon dilatation, and implantation of a second stent overlapping the first, both dilated to 10 mm diameter. One patient had elective redilatation of the stent six months after implantation, with further reduction of the gradient from 35 mm Hg to 10 mm Hg. At the latest follow up between three and 20 months (mean 12.2 months) after stent implantation, in four patients blood pressure was better controlled with antihypertensive drugs. One patient was normotensive without drugs. Computed tomography showed no aneurysm formation in the region of the stents.

Conclusions—Stent implantation is a preferable alternative to surgery in the treatment of patients with middle aortic syndrome and merits further evaluation.

Heart 1999;81:166–170

Keywords: middle aortic syndrome; stent implantation; paediatric cardiology; interventional cardiology

Middle aortic syndrome is an uncommon cause of upper limb hypertension. The clinical features may be similar to those of aortic coarctation, with upper limb hypertension and weak or absent femoral pulses, but the echocardiogram may not show coarctation at the usual site. In such patients, a localised, discrete, or long hypoplastic segment coarctation may be evident in the lower thoracic or upper abdominal aorta on magnetic resonance imaging or aortography. This disease has been named “middle aortic syndrome.” When a long segment hypoplasia occurs in this region, the treatment may be difficult. The treatment may consist of either attempts at balloon dilatation or surgical conduit bypass. While the surgical bypass presents technical difficulties in children, non-surgical treatment is not easy as the hypoplastic segment may or may not be amenable to balloon dilatation.

Balloon dilatation in aortic coarctation or recoarctation is successful in over 70% of cases, but the major determinant of success is the arch anatomy. There is a significant incidence of aneurysm formation, full thickness tears, and even death. Stent implantation may overcome some, if not all, of these complications. Stents have been used in various congenital heart defects, such as branch pulmonary artery stenosis, venous caval stenosis, and aortic recoarctation, in which balloon dilatation alone may produce unpredictable or unsatisfactory results. The application of stents has continued to widen. However, they have disadvantages in patients who have not reached their full growth.

We attempted stent implantation in five patients with middle aortic syndrome and present the early results and their outcome.

Methods

Patients

Five patients, aged between 4 and 17 years, mean 11.4 years, presented with upper limb hypertension, weak femoral pulses, and an audible systolic murmur over the back and precordium. The hypertension had been controlled with nifedipine alone in one. One patient (case 5), aged 4 years, had had a left thoracotomy because of a presumed diagnosis of a classic aortic coarctation.

Investigations

In all patients, cardiac catheterisation and angiography was performed under general anaesthesia by the femoral artery route using a 5 F or 6 F angiographic catheter. The clinical and haemodynamic data are given in table 1. The pressure gradient across the stenosis was...
between 40 and 90 mm Hg (mean 63.2 mm Hg). Angiography confirmed long segment stenosis in the mid or lower thoracic or upper abdominal aorta. The minimum diameter of the stenosis was between 2.5 mm and 5.0 mm and the length of the stenosis ranged between 3.5 cm and 8.3 cm. One patient (case 4), aged 8 years, had additional stenosis of the right renal artery and underwent successful balloon angioplasty of the stenotic artery immediately before stent implantation.

**STENT IMPLANTATION**

An 11 F transeptal sheath was inserted into the femoral artery in the three older patients and the carotid artery cut down approach was used in the remaining two, in whom 8 F sheaths were inserted. The carotid artery cut down approach was used in these two because of their small age and size for the insertion of an 8 F sheath in the femoral artery. The sheaths were positioned just distal to the stenosis. In four patients, the stents were mounted on Olbert balloons (Meditech Boston Scientific Corporation, Watertown, Massachusetts, USA) of 8–10 mm diameter and 4 cm length, and in one patient the stent was mounted on Powerflex balloon (Cordis Europe, Roden, the Netherlands) of 7 mm diameter and 4 cm length. Three Palmaz 5014, two Palmaz 4014, and one Palmaz 308 stents (Johnson and Johnson Intervention Systems, Warren, New Jersey, USA) were used at the initial procedure. The stent/balloon assembly was advanced through the sheath and positioned at the level of the stenosis. After withdrawal of the sheath, the balloon was gradually inflated to its nominal diameter up to a pressure of 10–20 atmospheres. Because gradual progressive dilatation over a period of several years was planned, the stents were not electively dilated to the diameter of the normal aorta above or below the stenosis. In one patient (case 2), the fully expanded stent did not cover the entire length of the stenosis and so a second Palmaz 4014 stent was placed overlapping the first Palmaz 5014 stent (table 1).

**Table 1  Procedure details**

<table>
<thead>
<tr>
<th></th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>13</td>
<td>15</td>
<td>17</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>59</td>
<td>54</td>
<td>64</td>
<td>20</td>
<td>15</td>
</tr>
<tr>
<td>Minimum diameter of stenosis (mm)</td>
<td>3.5</td>
<td>5</td>
<td>3.7</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Length of stenosis (cm)</td>
<td>5.5</td>
<td>8.3</td>
<td>4.2</td>
<td>3.5</td>
<td>4</td>
</tr>
<tr>
<td>Dimension of normal aorta proximal to stenosis (mm)</td>
<td>12</td>
<td>16</td>
<td>12</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Pressure proximal to stenosis before stent implantation (mm Hg)</td>
<td>160/110</td>
<td>186/120</td>
<td>120/70</td>
<td>100/70</td>
<td>170/80</td>
</tr>
<tr>
<td>Pressure distal to stenosis before stent implantation (mm Hg)</td>
<td>100/90</td>
<td>120/90</td>
<td>72/60</td>
<td>60/55</td>
<td>80/60</td>
</tr>
<tr>
<td>Gradient across stenosis before stent implantation (mm Hg)</td>
<td>60</td>
<td>65</td>
<td>50</td>
<td>40</td>
<td>90</td>
</tr>
<tr>
<td>Final stent diameter (mm)</td>
<td>6</td>
<td>10</td>
<td>8</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Pressure proximal to stenosis after stent implantation (mm Hg)</td>
<td>125/100</td>
<td>110/86</td>
<td>130/80</td>
<td>120/70</td>
<td>100/70</td>
</tr>
<tr>
<td>Pressure distal to stenosis after stent implantation (mm Hg)</td>
<td>112/90</td>
<td>102/66</td>
<td>95/75</td>
<td>120/70</td>
<td>90/70</td>
</tr>
<tr>
<td>Gradient across stenosis after stent implantation (mm Hg)</td>
<td>15</td>
<td>8</td>
<td>35</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Type and number of stents used</td>
<td>1 × 5014, 1 × 4014 (after thrombolytic treatment)</td>
<td>1 × 5014, 1 × 4014</td>
<td>1 × 5014</td>
<td>1 × 308</td>
<td>1 × 4014</td>
</tr>
</tbody>
</table>

**Figure 1** (A) Aortogram in patient 5 showing a long segment stenosis of the thoracic aorta. (B) Aortogram after stent implantation.
After the procedure, the patients were maintained on heparin for 48 hours and aspirin and anticoagulants (Sinthrome; Novarks, Surrey, UK) for three months. The antihypertensive treatment was also maintained after the procedure.

**Results**

Immediately after stent implantation, the residual gradient ranged between 0 and 35 mm Hg (mean 13.6 mm Hg) and there was a decrease in the aortic pressure above the stenosis in three of the five patients. Angiography showed a satisfactory result with widely patent (fig 1) and correctly positioned stents in all patients.

An important complication occurred in only one patient; thrombosis of the stent occurred six days after implantation (case 1). This was successfully treated with an infusion of alteplase (recombinant human tissue-type plasminogen activator) for three days. In this patient, at the time of the initial stent implantation the balloon had ruptured during inflation before full expansion (fig 2). Further inflation was not attempted. After thrombolytic treatment had shown recanalisation, additional balloon dilatation was performed, followed immediately by the implantation of a second stent overlapping the first, both of which were dilated to 10 mm diameter (fig 3). At the time of the investigation for suspected thrombosis and placement of catheters for the infusion of alteplase, manipulation of catheters and guidewires resulted in a dissection and small aneurysm of the distal part of the aorta, below the renal arteries and below the stents, which has been treated conservatively.

During the follow up period, varying between three and 20 months, blood pressure was well controlled with the previous treatment in four patients. Antihypertensive treatment has been withdrawn successfully in one patient after stent implantation. The femoral arterial pulses were easily palpable in all patients. Computed tomography showed no aneurysm formation in relation to the stents. In the patient in whom the first stent had thrombosed and another inserted, and in whom a dissection/aneurysm below the stents had been noted at follow up 14 months later, the blood pressure was controlled with the previous drug regimen and computed tomography showed a small aneurysm at the site of the dissection but none in relation to the stent. One patient (case 3) had elective redilatation of the stent six months after implantation. This resulted in a further reduction of the gradient from 35 mm Hg to 10 mm Hg.

In all patients spiral computed tomography, performed three to 12 months after stent implantation, confirmed satisfactory anatomical results.

**Discussion**

Balloon dilatation is considered an acceptable alternative treatment to surgery in patients with aortic recoarctation. It produces satisfactory results in over 70% of the patients. However, there is a small risk of aneurysm formation. The anatomy of the aortic arch is usually important in determining the results. Although balloon dilatation of native aortic coarctation has its proponents, it is not universally accepted and may be considered a controversial or investigational alternative to surgery. The complications of balloon dilatation, both of native coarctation and recoarctation, include acute aneurysm formation, dissection of the aorta, pseudoaneurysm, and even rupture of the aorta leading to death. Intimal tears are an inherent part of the mechanism of balloon dilatation and cannot be controlled. In experimental balloon dilatation of excised specimens of aortic coarctation, tears in the vessel wall were present in all the specimens and histologically these tears extended to the intimal and medial layers. These histological findings were confirmed by several studies in both animal models of aortic coarctation as well as in patients who were evaluated by intravascular ultrasound before

![Figure 2](image-url)
and after balloon dilatation of aortic coarctation. Intravascular ultrasound appears to be more sensitive than angiography in detecting vascular wall changes, and during the follow up evaluation the tears in the intima may decrease and not progress to aneurysms. Stent implantation, certainly in aortic recoarctation and possibly in native coarctation, may be a better alternative to balloon dilatation and its role is currently being evaluated.

Stents have the advantage of avoiding overdilatation of the stenotic segment and thus the extent of intimal injury may be more limited. Dilatation of the vessel by stents is thus more controlled and predictable and recoil of the stenotic lesion is avoided. Experimental studies have shown that neointimal formation occurred wherever the stent was in contact with the aortic wall and there was no significant intimal or medial injury. Furthermore, stents can be redilated after the patient has grown.

Middle aortic syndrome is a difficult clinical problem to deal with. It is an uncommon cause of upper limb hypertension and is often detected during the investigation of hypertension. While it occurs as an isolated abnormality, it may be associated with neurofibromatosis, eosinophilia, Williams’ syndrome, Takayasu’s arteritis, and additional renal artery stenosis. Balloon dilatation has been attempted with some success on occasions, but the results may be unpredictable and unsatisfactory. The mechanism of balloon dilatation is similar to dilatation of coarctation and tears may be seen on intravascular ultrasound. Surgical bypass using conduits is difficult and complicated and the tube graft may need to be replaced at a later date, especially if the patient has not reached full growth at the time of the initial surgical treatment. The type of surgery may involve thoracoabdominal to infrarenal aortic bypass with renal artery reimplantation, splenorenal bypass, aortorenal bypass, and autotransplantation.

In our limited initial experience, stent implantation has been attempted in five patients with middle aortic syndrome. In all patients, the stents were dilated electively to less than their optimal size and less than the size of the normal aorta on either side of the stenosis in an attempt to avoid overdilatation. The lumen diameter was between 2.5 and 5 mm and thus the vessel size was approximately doubled by the implanted stent. However, as a result of this approach, in one patient thrombosis of the stent occurred six days after implantation. In this patient, because of balloon rupture a suboptimal expansion of the stent had been accepted. Within a week, further balloon dilatation and implantation of another stent improved the result. We believe that gradual progressive dilatation over a period of a few months or even years, especially when keeping pace with the growth of the patient, would allow the intimal injury to heal before the next dilatation. In one patient, elective redilatation of the stent was successfully performed six months after implantation. This tends to support our clinical experience and that of other studies, suggesting that stents can be redilated even when completely covered with neointima.

Stent implantation in the treatment of patients with middle aortic syndrome is less invasive than surgery, produces satisfactory early results, and merits further evaluation.